Stockholders' Equity (Deficit) - Additional Information (Details) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended
	Sep. 03, 2021 shares	Aug. 09, 2021 USD ($) $ / shares shares	Aug. 21, 2020 USD ($) $ / shares shares	Aug. 11, 2020	Sep. 30, 2021 $ / shares shares	Sep. 30, 2020 shares	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) shares	Dec. 31, 2020 $ / shares
Class Of Stock [Line Items]
Reverse stock split ratio, description				1-for-8.215
Reverse stock split ratio				0.1217
Preferred stock, conversion basis				1-for-8.215
Preferred stock conversion ratio				0.1217
Proceeds from issuance of common stock			$ 135,435				$ 30,000
Net proceeds from initial public offering								$ 147,628
Common stock, voting rights							one vote for each share
Noncash stock compensation expense							$ 11,461	$ 1,870
Common stock, par value | $ / shares					$ 0.00001		$ 0.00001		$ 0.00001
OrbiMed Royalty & Credit Opportunities, LP.
Class Of Stock [Line Items]
Issuance of shares upon initial public offering | shares	221,511
Common Stock
Class Of Stock [Line Items]
Issuance of shares upon initial public offering | shares					1,270,462	6,151,162	1,270,462	6,151,162
Common Stock | Blackstone Alternative Credit Advisors ("Blackstone")
Class Of Stock [Line Items]
Number of shares sold | shares		1,048,951
Shares issued, price per share | $ / shares		$ 28.60
Proceeds from issuance of common stock		$ 30,000
Common stock, par value | $ / shares		$ 0.00001
Common Stock | IPO
Class Of Stock [Line Items]
Issuance of shares upon initial public offering | shares			6,151,162
Shares issued, price per share | $ / shares			$ 24.00
Net proceeds from initial public offering			$ 135,435
Underwriting discounts and commissions and offering expenses			$ 12,193
Common Stock | Over-Allotment Option
Class Of Stock [Line Items]
Issuance of shares upon initial public offering | shares			802,325